ClinicalTrials.gg
Not yet recruitingNCT06564883Updated Aug 21, 2024

Hydration and Acceptability of the Genital and Skin Mucosa of a Vaginal Moisturizer in Menopausal Women

A Phase 3 interventional study of 0.20% sodium hyaluronate gel in Vaginismus, Vaginal Atrophy and Menopause, sponsored by Biolab Sanus Farmaceutica. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Biolab Sanus Farmaceutica · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Sex
Female
01

Study summary

Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours. Hyaluronic Acid promotes vaginal moisture, providing symptom relief in various situations such as:

  • Vaginismus and other sexual dysfunctions related to penetration
  • Users of hormonal contraceptives with lubrication loss
  • Postpartum and lactational period
  • Post antibacterial or antifungal therapies
  • During systemic oncological treatments (chemotherapy, radiotherapy, hormone therapy)
  • Climacteric (urogenital atrophy)
  • Post urogynecological surgeries (correction of urinary incontinence, genital dystopias, etc.)
  • Post vulvovaginal abrasive, chemical, laser, or high-frequency therapies
  • Post cosmetic and genital rejuvenation therapies
02

Conditions studied

  • Vaginismus
  • Vaginal Atrophy
  • Menopause

Browse trials for

03

In context

Vaginismus

29 studies on the registry are indexed under Vaginismus; 9 are open to participants now.

This study's planned enrollment of 45 is above the median of 40 across 23 interventional studies indexed under Vaginismus.

Browse Vaginismus studies →

Lead sponsor

Biolab Sanus Farmaceutica is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy research participants, with an active sexual life;
  • Intact skin and mucosa in the test region;
  • Participants vaccinated for COVID-19 (Corona virus Disease).
  • Agreement to adhere to the study procedures and requirements and attend the institute on the day(s) and time(s) determined for the assessments;
  • Ability to consent to participate in the study;
  • Menopausal participants of any age, without systemic or topical hormone replacement therapy in the last 6 months
  • Presenting mild to moderate vaginal dryness (≥0.5 and \<7.5) - according to the Visual Analogic Scale
  • Healthy research participants, with an active sex life (at least once a week)

Exclusion criteria

Exclusion Criteria:

  • Skin pathology in the area of product application;
  • Decompensated Diabetes Mellitus (TBD by the institute together with the sponsor);
  • Immune insufficiency;
  • Current use of the following topical or systemic medications: , and antihistamines;
  • Skin diseases: vitiligo, psoriasis, atopic dermatitis;
  • Previous reaction to the category of the product tested;
  • Other illnesses or medications that may directly interfere with the study or put the health of the research participant at risk.
  • Have used vaginal moisturizing creams and/or intimate lubricants 5 days before the initial study visit;
  • Have had sexual intercourse at least 48 hours before the initial study visit;
  • Have been diagnosed with a urogenital or vaginal infection in the last 30 days;
  • Have used topical or systemic antibiotics, antifungals, hormone-based creams or treatment for vaginal atrophy in the last 30 days.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Experimental Arm

    Hyaluronic Acid will applied under recommended conditions during the period of T22 ±2 days.

    Device: 0.20% sodium hyaluronate gel

Interventions

  • Device0.20% sodium hyaluronate gel

    Hyaluronic Acid is indicated for the relief of vaginal dryness, itching, and irritation, or the reduction of vaginal lubrication with prolonged hydration effects for up to 72 hours.

    Also known as: Hyaluronic Acid

06

What researchers measure

Primary outcomes

  1. Verify the hydration of the cutaneous and genital mucosa after using hyaluronic acid-based vaginal gel

    To evaluate the perceived hydration effectiveness, a visual analogue scale will be used, where the minimum value (zero) represents no dryness and the maximum value (ten) represents extremely dryness. Lower scores indicate improved vaginal hydration.

    Time frame: 22 days

  2. Verify the acceptability of the cutaneous and genital mucosa after using hyaluronic acid-based vaginal gel

    To assess skin acceptability, an epithelial integrity questionnaire will be used, where a score, on a 5-point scale, will be assigned after evaluation by the gynecologist. The lowest score will be 1, representing "petechiae before contact" and the maximum score will be 5 with "thin, non-friable mucosa". The higher the score, the healthier and more intact the epithelium will be.

    Time frame: 22 days

Secondary outcomes

  1. Relief of pruritus after using hyaluronic acid-based vaginal gel

    The relief of pruritus assessment will be evaluates through an Visual Analogic Scale. Where the minimum value (zero) represents no pruritus and the maximum value (ten) represents extremely pruritus. Lower scores indicate improvement or absence of vaginal pruritus.

    Time frame: 22 days

  2. Verify the maintenance of pH after using Hyaluronic Acid when applied under recommended conditions of use through gynecologist follow-up during the use.

    pH maintenance will be assessed using reagent strips.

    Time frame: 22 days

  3. Verify the maintenance of vaginal microbiota after using Hyaluronic Acid when applied under recommended conditions of use through gynecologist follow-up during the use.

    Bacterioscopic collection of vaginal contents using a sterile swab. The swabs containing the samples will be placed in test tubes sent to the laboratory for microbiological analysis.

    Time frame: 22 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Sep 2025, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2024
First posted
Aug 21, 2024
StartEst.
Mar 1, 2025
Primary completionEst.
Sep 30, 2025
CompletionEst.
Oct 30, 2025
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06564883
Lead sponsor
Biolab Sanus Farmaceutica
Responsible party
Sponsor
First posted
Aug 21, 2024
Start date
Mar 1, 2025 (estimated)
Primary completion
Sep 30, 2025 (estimated)
Completion
Oct 30, 2025 (estimated)
Last update
Aug 21, 2024

Study contacts

Samuel Guerra Filho, MD
Contact
negocios@grupoinvestiga.com
+55 19 37898610

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion